

Evaluating & Collecting Data on Medication-Based Treatment in Corrections

Amanda Latimore, PhD


Public Sector Initiatives Lead, Bloomberg American Health Initiative

Assistant Scientist, Department of Epidemiology

July 16, 2020

Johns Hopkins Bloomberg School of Public Health


Rhode Island 60% reduction in deaths



Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018). Post-incarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. *JAMA Psychiatry*, 75(4), 405-407. doi:10.1001/jamapsychiatry.2017.4614



Effectiveness of Medications for Opioid Use Disorder in Prisons and Jails



Increased community treatment engagement



Reduced illicit opioid use



Reduced injection drug use

Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA (2019). Effectiveness of Medication Assisted Treatment for Opioid Use in Prison and Jail Settings: A Meta-Analysis and Systematic Review *J Subst Abuse Treat*; 99, 32–43. doi:10.1016/j.jsat.2018.12.003




Making the Case

- 1. Efficient use of limited resources:** Identifying priorities and focusing efforts
- 2. Better outcomes:** Identifying the source of the problem means you're pulling the right lever for change
- 3. Solutions that are responsive and nimble:** Keeping track of progress, forecasting, evolving needs, changing environment
- 4. Communicating the problem and advocating for resources:** Data + stories are effective, and particularly important for highly stigmatized population (incarcerated individuals) and outcome (addiction)



METRICS



Considerations

- Type of medication
- Length of stay
- Type of medication
- Racial/ethnic and other treatment disparities
- Continuation vs Initiation
- Indirect impacts (e.g., suicides, noise, disciplinary events)
- Data collection infrastructure, access
- Policies that may be driven by stigma

Mace, S., Siegler, A. Wu, K., Latimore, A., & Flynn, H. The National Council for Behavioral Health and Vital Strategies. (2020). Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning and Implementation Toolkit.

<https://www.thenationalcouncil.org/medication-assisted-treatment-for-opioid-use-disorder-in-jails-and-prisons/>



Implementing Jail-Based MOUD Programs in New Jersey

In Jail		Pre-Trial Release	Awaiting trial or Sentenced	Total
1	The total number of inmates anticipated to be admitted during the Contract period.	N/A	N/A	
2	The number of inmates anticipated to screen positive for Substance Use Disorders during the Contract period.			0
3	The number of inmates anticipated to screen positive for Opioid Use Disorders during the Contract period.			0
Inmates who are part of the MAT Initiative (include only those on Gov./SOR funding)				
In Jail		Pre-Trial Release	Awaiting trial or Sentenced	Total
4	Targeted number of inmates eligible for the program.			0
5	Targeted number of inmates who were offered MAT.			0
6	Targeted number of inmates who accepted MAT.			0
7	Targeted number of inmates placed on Methadone.			0
8	Targeted number of inmates placed on Buprenorphine.			0
9	Targeted number of inmates placed on Sublocade.			0
10	Targeted number of inmates placed on oral Naltrexone.			0
11	Targeted number of inmates placed on Vivitrol.			0
Total number of inmates on MAT (7 to 11)		0	0	0
Release		Pre-Trial Release	Awaiting trial or Sentenced	Total
12	Targeted number of people on MAT at time of release.			0
13	Targeted number of people provided a warm handoff to an Opioid Treatment Provider (OTP) or other MAT provider.			0
14	Targeted number of people assigned a peer specialist for follow-up.			0
15	Targeted number of people provided a case manager by a community provider or by jail staff.			0
16	Targeted number of people who are released to dependent living/institutional living.			0
17	Targeted number of people who are released to independent living.			0
18	Targeted number of people transferred from jail to DOC custody.			0
19	Targeted number of people who are released as homeless- to shelter.			0
20	Targeted number of people who are released as homeless- to streets.			0
Total Number of people who are homeless (19 & 20)		0	0	0
<i>The information below can be collected by case managers, peer recovery specialists, re-entry specialists or the individual's phone number.</i>				
Post Release		Pre-Trial Release	Awaiting trial or Sentenced	Total
21	Targeted number of people who maintain MAT 3 months post release.			0
22	Targeted number of people who maintain MAT 6 months post release.			0
23	Targeted number of people who maintain MAT 9 months post release.			0
24	Targeted number of people who are employed within 6 months of release.			0
25	Targeted number of people who are in stable independent housing within 6 months of release.			0
26	Targeted number of opioid overdose deaths from the treated population (within 30 days post release).			0
27	Targeted number of opioid overdose deaths from the treated population (within 3 months post release).			0
28	Targeted number of opioid overdose deaths from the treated population (within 6 months post release).			0
Recidivism		Sentencing	Violation of Terms of Release	ew Charg
29	Targeted number of people returning to jail within 3 months.	0	0	0
30	Targeted number of people returning to jail within 6 months post release.	0	0	0
31	Targeted number of people returning to jail within 9 months post release.	0	0	0

Shared with permission from the New Jersey Office of Treatment & Recovery Support, DMHAS/DHS



	H	L	AB	AJ	AK	AL	AM	AO	AP	AQ	AR	AS	AT	AU
1	LAST NAME	DOB	DATE ACCEPTED MAT	RE-ENTER INMATE NUMBER	MAT START MONTH	MAT START DAY	MAT START YEAR	DAYS BETWEEN ACCEPT & START	CHANGED MIND & ACCEPTED MAT	HEALTH INSURANCE AT INTAKE	TREATMENT CONTINUATION	TYPE OF MAT PRESCRIBED AT INTAKE	EARLY DISCONTINUED MAT?	MAT DISCONTINUE - MONTH
2	Klm	01/02/1980			01 - Jan	31	2020		No Change	Medicaid	None	Methadone	No	
3	Qrs	03/02/1970	01/03/2020		01 - Jan	07	2020	4	No Change	Medicaid	Buprenorphine	Buprenorphine	Yes	01 - Jan
4	Wxy	01/02/1971	01/04/2020		01 - Jan	07	2020	3	No Change	No Insurance	None	Buprenorphine	No	
5	Aab	01/02/1985	02/02/2020		02 - Feb	26	2020	24	No Change	Medicaid	Buprenorphine	Buprenorphine	Yes	02 - Feb
6	Fgh	03/02/1985	01/31/2020		02 - Feb	01	2020	1	No Change	Private Insuran	Vivitrol	Buprenorphine	No	
7	Qrs								Changed No to	Non-Reporting	None	Vivitrol		
8	Def	05/21/2000												

Ready INTAKE **ACCEPTED MAT** RELEASE ANNEX A - MONTHLY CHARTS

ACCEPTED MAT

Type of MAT	
Methadone	1
Buprenorphine	4
Sublocade	0
Oral Naltrexone	0
Vivitrol	1
Total	6




*Among those accepted MAT

Treatment Continuation	
None	3
Treatment Continuation	3
Unknown	0
Total	6

*Among those accepted MAT

Early MAT Discharge	
Early MAT discharge	2
Retained in treatment	3
Unknown	0
Total	5

*Retained during incarceration among those started



Seeking Change Agents

Bloomberg Fellows receive a full-tuition scholarship to earn a Master of Public Health degree from the nation's leading school of public health.

Fellows can attend either full- or part-time, on campus or online. Degree candidate must apply with support from the organization for which they work, with a focus in one of the following areas:

Addiction and
Overdose

Environmental
Challenges

Obesity and
the Food
System

Adolescent
Health

Violence

Explore the Bloomberg Fellows Program at:
americanhealth.jhu.edu/fellowship

Contact

Amanda Latimore, PhD

Public Sector Initiatives Lead,
Bloomberg American Health Initiative

Assistant Scientist,
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Email: alatimore@jhu.edu

Website: <http://americanhealth.jhu.edu>

Twitter: @LatimoreAmanda

